Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes

Urology

Volumn 67, Issue 6, 2006, Pages 1235-1240

  Oh, William K ^a   Manola, Judith ^a   Babcic, Vladana ^a   Harnam, Neesha ^a   Kantoff, Philip W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; HORMONAL THERAPY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; PACLITAXEL; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 33744512301     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.01.006     Document Type: Article

References (21)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics 2005. CA Cancer J Clin 55 (2005) 10-30
2. Debes J.D., and Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351 (2004) 1488-1490
3. Crawford E., Eisenberger M., McLeod D., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 (1989) 419-424
4. Gilligan T., and Kantoff P.W. Chemotherapy for prostate cancer. Urology 60 (2002) 94-100
5. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer. results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17 (1999) 2506-2513
6. Tannock I.F., Osaba D., Stockler M., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer. a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
7. Tannock I.F., Wit R.D., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
8. Petrylak D.P., Tangen C.M., Hussain M., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
9. Rosenberg J., and Small E.J. Secondary chemotherapy. has the time come?. Clin Prostate Cancer 3 (2004) 122-124
10. Rosenberg J., Kelly W.K., Michaelson M.D., et al. A randomized phase II study of ixabepilone or mitoxantrone and prednisone (MP) in patients with taxane-refractory hormone refractory prostate cancer (HRPC). (abstract). Proc Am Soc Clin Oncol 23 (2005) 4566
11. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer. recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 (1999) 3461-3467
12. Cox D.R. Analysis of Binary Data. (1970), Methuen, London
13. Mehta C.R., Patel N.R., and Tsiatis A.A. Exact significance testing for ordered categorical data. Biometrics 40 (1984) 819-825
14. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
15. Peto R., and Peto J. Asymptotically efficient rank invariant test procedures. J Royal Stat Soc A 135 (1972) 185-206
16. Cox D.R. Regression models and life tables. J Royal Stat Soc B 34 (1972) 181-220
17. Joshua A.M., Nordman I., Venkataswaran R., et al. Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer. Intern Med J 35 (2005) 468-472
18. Beekman K.W., Fleming M.T., Scher H.I., et al. Second-line chemotherapy for prostate cancer. patient characteristics and survival. Clin Prostate Cancer 4 (2005) 86-89
19. Urakami S., Yoshino T., Kikuno N., et al. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer. a pilot study. Urology 65 (2005) 543-548
20. Oh W.K., George D.J., and Tay M.H. Response to docetaxel plus carboplatin in patients who have progressed on taxane chemotherapy. Clin Prostate Cancer 4 (2005) 61-64
21. Sternberg C.N., Whelan P., Hetherington J., et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68 (2005) 2-9